Association of Lipid Profile and Liver Parameters with Different Grades of Non-alcoholic Fatty Liver Disease

Document Type : Original Article

Authors

Department of Biochemistry, Shyam Shah Medical College, Rewa, India

Abstract

Background and aim: The present study aimed to determine lipid profile and liver function tests in patients with non-alcoholic fatty liver disease (NAFLD) and examine their possible association with various degrees of NAFLD.
Material and methods: Fifty patients with NAFLD were enrolled in this cross-sectional study, and their serum lipids and liver parameters were analyzed.
Results: Serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL) levels were increased in 54%, 68%, 42%, and 38% of NAFLD patients, respectively. Serum high-density lipoprotein (HDL) levels were decreased in 36% of NAFLD patients. Similarly, serum aspartate transaminase (AST), alanine transaminase (ALT), and total bilirubin were increased in 60%, 58%, and 52% of NAFLD patients, respectively whereas total protein levels were decreased in 38% of NAFLD patients. Increasing grades of NAFLD were substantially associated with increasing serum TC, TG, VLDL, AST, ALT, and total bilirubin. At the same time, HDL and total protein levels were decreasing.
Conclusions: A dyslipidemic pattern of lipid markers and abnormal liver function tests were observed in patients with NAFLD. Dyslipidemia and increased AST and ALT levels were also associated with increasing degrees of fatty liver in patients with NAFLD.

Keywords

Main Subjects


[1] Abdel-Rahman RF. Non-alcoholic fatty liver disease: Epidemiology, pathophysiology and an update on the therapeutic approaches. Asian Pacific Journal of Tropical Biomedicine. 2022;12(3):99-114. https://doi.org/10.4103/2221-1691.338919.
[2] Abd El-Kader SM, El-Den Ashmawy EM. Non-alcoholic fatty liver disease: The diagnosis and management. World journal of hepatology. 2015;7(6):846-58. https://doi.org/10.4254/wjh.v7.i6.846.
[3] Byrne CD, Targher G. NAFLD: a multisystem disease. Journal of hepatology. 2015;62(1):S47-64. https://doi.org/10.1016/j.jhep.2014.12.012.
[4] Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC, et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PloS one. 2017;12(3):e0173499. https://doi.org/10.1371/journal.pone.0173499.
[5] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta‚Äźanalytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. https://doi.org/10.1002/hep.28431.
[6] Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030. Journal of hepatology. 2018;69(4):896-904. https://doi.org/10.1016/j.jhep.2018.05.036.
[7] Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672-82. https://doi.org/10.1002/hep.30251.
[8] Fierabracci P, Tamberi A, Santini F. Obesity-related comorbidities. Minimally Invasive Bariatric and Metabolic Surgery: Principles and Technical Aspects. 2015:25-34. https://doi.org/10.1007/978-3-319-15356-8_4.
[9] Shahab O, Biswas R, Paik J, Bush H, Golabi P, Younossi ZM. Among patients with NAFLD, treatment of dyslipidemia does not reduce cardiovascular mortality. Hepatology communications. 2018;2(10):1227-34. https://doi.org/10.1002/hep4.1241.
[10] Mahale AR, Prabhu SD, Nachiappan M, Fernandes M, Ullal S. Clinical relevance of reporting fatty liver on ultrasound in asymptomatic patients during routine health checkups. Journal of International Medical Research. 2018;46(11):4447-54. http://dx.doi.org/10.1177/0300060518793039.
[11] Zou Y, Zhong L, Hu C, Sheng G. Association between the alanine aminotransferase/aspartate aminotransferase ratio and new-onset non-alcoholic fatty liver disease in a nonobese Chinese population: a population-based longitudinal study. Lipids in health and disease. 2020;19(1):1-10. https://doi.org/10.1186/s12944-020-01419-z.
[12] Swain M, Nath P, Parida PK, Narayan J, Padhi PK, Pati GK, et al. Biochemical profile of nonalcoholic fatty liver disease patients in eastern India with histopathological correlation. Indian Journal of Clinical Biochemistry. 2017;32:306-14. https://doi.org/10.1007/s12291-016-0612-7.
[13] Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PloS one. 2015;10(10):e0140908. https://doi.org/10.1371/journal.pone.0140908.
[14] Rashidmayvan M, Mohammadshahi M, Seyedian SS, Haghighizadeh MH. The effect of Nigella sativa oil on serum levels of inflammatory markers, liver enzymes, lipid profile, insulin and fasting blood sugar in patients with non-alcoholic fatty liver. Journal of diabetes & metabolic disorders. 2019;18:453-9. https://doi.org/10.1007/s40200-019-00439-6.
[15] Jain P, Parate R, Dubey T, Jain R. Prevalence of NAFLD (non-alcoholic fatty liver disease) in metabolic syndrome and their correlation with various biochemical and serologic parameters for early detection and detecting patients of lean Nash (Non-alcoholic steatohepatitis). Prevalence. 2018;3(2):24-8.
[16] Friedwald WT. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem. 1972;18:499-502.
[17] Khanal UP, Paudel B, Gurung G, Hu YS, Kuo CW. Correlational study of nonalcoholic fatty liver disease diagnosed by ultrasonography with lipid profile and body mass index in adult nepalese population. Journal of medical ultrasound. 2019;27(1):19-25. https://doi.org/10.4103/JMU.JMU_53_18.
[18] Khalil F, Nabil M, Salah M, Mohamed MA, Ibrahim W. Study of lipid profile in different grades of non-alcoholic fatty liver disease. The Egyptian Journal of Hospital Medicine. 2018;73(8):7388-93. https://dx.doi.org/10.21608/ejhm.2018.18473.
[19] Mansour-Ghanaei R, Mansour-Ghanaei F, Naghipour M, Joukar F. Biochemical markers and lipid profile in nonalcoholic fatty liver disease patients in the PERSIAN Guilan cohort study (PGCS), Iran. Journal of Family Medicine and Primary Care. 2019;8(3):923-8. https://doi.org/10.4103/jfmpc.jfmpc_243_18.
[20] Pardhe BD, Shakya S, Bhetwal A, Mathias J, Khanal PR, Pandit R, et al. Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal. BMC gastroenterology. 2018;18:1-8. https://doi.org/10.1186/s12876-018-0843-6.
[21] Bhusal KR, Simkhada R, Nepal P. Lipid profile in different grades of ultrasonic non-alcoholic fatty liver disease. Journal of College of Medical Sciences-Nepal. 2017;13(2):258-61.
[22] Ramesh KD, Indumati V, Vijay V. Rajeshwari. Comparison of lipid profile and de-ritis ratio in ultrasound diagnosed non-alcoholic and alcoholic fatty liver disease. International Journal of Clinical Biochemistry and Research. 2016;3(4):438-41.
[23] Namoos K, Shabbir W. Role of Lipid profile and Biochemical markers in Non-alcoholic Fatty Liver Disease patients in tertiary care hospital, Lahore. 2021;13(1):43-47.
[24] Zakeri A, Karamat-Panah S. Prevalence of non-alcoholic fatty liver disease and its risk factors in patients referred to Ardabil city hospital during 2015-2016. Int J Community Med Pub Health. 2018;5:917-21. http://dx.doi.org/10.18203/2394-6040.ijcmph20180747.
 [25] Maharjan P, Khanal P, Parajuli NP, Joshi G, Parajuli H, Khanal S, et al. Biochemical changes in non-alcoholic fatty liver disease (NAFLD): a study in nepalese population. Annals of Clinical Biochemistry. 2016;2(2):15-20. http://dx.doi.org/10.3126/acclm.v2i2.15597.
Volume 5, Issue 1
March 2023
Pages 1-6
  • Receive Date: 14 January 2023
  • Revise Date: 23 February 2023
  • Accept Date: 06 March 2023
  • First Publish Date: 09 March 2023